# Semaglutide

> FDA-approved GLP-1 agonist for diabetes and obesity.

Source: https://peptides.cafe/peptide/semaglutide
Category: Metabolic · Incretin
Tag: Weight loss

## Mechanism
A long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1 receptors.

## Research areas
- Type 2 diabetes (Ozempic, Rybelsus)
- Obesity / chronic weight management (Wegovy)
- Cardiovascular risk reduction (SELECT trial)

## Common research protocols
- Weekly subcutaneous clinical use: Stepwise dose escalation to manage GI tolerability in approved indications.

## Study summaries
- "Semaglutide for weight loss in adults with overweight or obesity (STEP 1)" — New England Journal of Medicine (2021): Mean ~15% weight loss at 68 weeks versus placebo.
- "Cardiovascular outcomes with semaglutide (SELECT)" — New England Journal of Medicine (2023): Reduced MACE in adults with CVD and overweight/obesity.

## Considerations
- FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- Requires physician oversight and prescription.
- Compounded versions vary in quality.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.